{"title":"妊娠早期慢性高血压:血管紧张素转换酶抑制剂的新应用?","authors":"L. S. Bezerra, M. Santos-Veloso, S. G. Lima","doi":"10.33552/WJGWH.2019.02.000526","DOIUrl":null,"url":null,"abstract":"Cardiovascular diseases are a major cause of maternal mortality and morbidity worldwide, including developed countries [1]. The first-line drug to treat hypertension in pregnant women is methyldopa, which is an α2-adrenergic agent that has shown maternal and fetal safety and efficacy. However, methyldopa is not effective in all cases, and sometimes it is important to consider other pharmacological agents [1,2].","PeriodicalId":87379,"journal":{"name":"World journal of gynecology & womens health","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chronic Hypertension During the First Trimester of Pregnancy: What is New About the Use of Angiotensin-Converting Enzyme Inhibitors?\",\"authors\":\"L. S. Bezerra, M. Santos-Veloso, S. G. Lima\",\"doi\":\"10.33552/WJGWH.2019.02.000526\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cardiovascular diseases are a major cause of maternal mortality and morbidity worldwide, including developed countries [1]. The first-line drug to treat hypertension in pregnant women is methyldopa, which is an α2-adrenergic agent that has shown maternal and fetal safety and efficacy. However, methyldopa is not effective in all cases, and sometimes it is important to consider other pharmacological agents [1,2].\",\"PeriodicalId\":87379,\"journal\":{\"name\":\"World journal of gynecology & womens health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World journal of gynecology & womens health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33552/WJGWH.2019.02.000526\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of gynecology & womens health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33552/WJGWH.2019.02.000526","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chronic Hypertension During the First Trimester of Pregnancy: What is New About the Use of Angiotensin-Converting Enzyme Inhibitors?
Cardiovascular diseases are a major cause of maternal mortality and morbidity worldwide, including developed countries [1]. The first-line drug to treat hypertension in pregnant women is methyldopa, which is an α2-adrenergic agent that has shown maternal and fetal safety and efficacy. However, methyldopa is not effective in all cases, and sometimes it is important to consider other pharmacological agents [1,2].